Pembrolizumab for classical Hodgkin lymphoma
NICE/NHS England recommend pembrolizumab for people with relapsed or refractory Hodgkin lymphoma who have had brentuximab vedotin and cannot have an autologous stem cell transplant
News
New treatments and drug approvals
Read the latest news and views from Lymphoma Action.
Use the drop down filter to find the most relevant news for you.
New CLL guidelines published
The British Society of Haematology have published their guidelines on the treatment of chronic lymphocytic leukaemia
BSH publish new mantle cell lymphoma guidelines
New guidelines give a clear treatment pathway for people with mantle cell lymphoma
First CAR T-cell therapies recommended for approval in Europe
These therapies offer a new treatment option for people with difficult-to-treat B cell lymphomas.
Biosimilars in the real world
Stephen Scowcroft reports back from a biosimilars panel at the European Haematology Association (EHA) Congress 2018.
Brentuximab vedotin now into routine use
New evidence means the targeted drug can now be used routinely on the NHS for more people with classical Hodgkin lymphoma.
Antibody to benefit people with untreated follicular lymphoma
NICE recommends obinutuzimab (Gazyvaro) to be considered as part of first-line treatment for advanced follicular lymphoma.
Obinutuzumab not recommended for untreated follicular lymphoma in Scotland
Scottish Medicines Consortium chooses not to recommend obinutuzumab for treatment of follicular lymphoma.
NICE recommends ibrutinib for relapsed or refractory mantle cell lymphoma
NICE reverses its decision on ibrutinib for relapsed or refractory mantle cell lymphoma.
NICE recommends ibrutinib for relapsed or refractory mantle cell lymphoma
NICE reverses decision on Ibrutinib and recommends it for baseline commissioning in England.